Titlebook: Liver Radioembolization with 90Y Microspheres; José I. Bilbao (Professor),Maximilian F. Reiser (P Book 20081st edition Springer-Verlag Ber

曲解

Identification of Candidates and Selection Criteria,cinoma, pancreas carcinoma, breast cancer or other tumor types will develop metastases within the liver during the follow-up period [1]. There is no doubt that surgical resection of these metastases is the only potential curative option for these patients and is therefore considered as gold standard

Facilities

Radiological Evaluation of Patients with Liver Tumors,atients with liver disease (e.g. the increasing number of patients with viral hepatitis) or with at least potential involvement of the liver (e.g. patients with extrahepatic malignancies such as colonic carcinoma). The aim of imaging has to be an accurate assessment of number, size and localization

Expediency

LUCY

Radioembolization : Identifying and Managing Anatomic Variants,scribed in the literature, the characterization and understanding of regional hepatic perfusion in the context of radioembolization continues to be studied in great depth. The aim of this chapter is to provide a thorough discussion and detailed presentation of the management of arterial variants wit

窗簾等

Posimetry and Dose Calculation,e activity (GBq) of yttrium-90 (.Y) delivered to the target organ. Classically, dosimetry is a Radiation Oncology term for the estimation of the absorbed dose expressed in units of Gy of radiation in tissue that will be or has been delivered. For microsphere treatment, it is more appropriate to desc

LAVA

sebaceous-gland

Radiological Detection and Assessment of Tumor Response,g on the primary tumor. Even if this fact represents the final status of a malignancy, about half of all patients dying from a malignant disease will have apparent hepatic métastases. The risk of developing hepatic metastases varies widely among different types of primary malignancy.

沉默

Results in Hepatocellular Carcinoma,dustrialized world [1]. Prognosis has improved in the last two decades, mainly because of earlier detection of the disease, at stages were potentially curative therapies can be applied, including surgical resection, liver transplantation and either chemical (ethanol, acetic acid) or physical (radiof

有雜色

Results in Liver Metastatic Colorectal Cancer,tients will not be candidates for potentially curative surgical resection and therefore must rely on other local therapies to augment systemic cheotherapy. Unlike some other solid tumors with liver métastases, mCRC patients now have access to a plethora of new biologic agents and cytotoxic drugs tha

macabre